Analysts See $-0.10 EPS for Critical Outcome Technologies Inc. (COTQF)

December 12, 2017 - By Winifred Garcia

 Analysts See $ 0.10 EPS for Critical Outcome Technologies Inc. (COTQF)

Analysts expect Critical Outcome Technologies Inc. (OTCMKTS:COTQF) to report $-0.10 EPS on December, 18.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.1 EPS. It closed at $0.7643 lastly. It is down 0.00% since December 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company has market cap of $13.28 million. The Company’s lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, as well as head and neck squamous cell carcinoma. It currently has negative earnings. The firm also develops COTI-219, a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function; drug candidates for the treatment of acute myelogenous leukemia, SOX9, MRSA, multiple sclerosis, and AlzheimerÂ’s disease; and HIV integrase inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.